Cellyrix Therapeutics

TargetingTumor Heterogeneity

Health Tech & Life Sciences
Private
Follow

Company Overview

Snapshot

Founded in December 2024 by Eran Kotler, Avishai Gavish, and Mordechai Applebaum, Cellyrix Therapeutics operates with 1–10 employees. The company secured pre-seed funding in December 2024 from AION Labs.

Business overview

Cellyrix Therapeutics is a Health Tech & Life Sciences company focused on developing novel cancer treatments. Leveraging breakthroughs in single-cell sequencing and artificial intelligence, the company aims to understand and address tumor heterogeneity, which is a key factor in therapy resistance, metastasis, and relapse. Cellyrix operates in the Pharma & Medical Biotechnology sector, specifically in Drugs Discovery & Development, targeting the Life Sciences and Pharmaceutical industries with its B2B business model.

Log in to access full profile

Company Intelligence Q&A

When was Cellyrix Therapeutics founded?
Cellyrix Therapeutics was founded in December 2024.
Who are the founders of Cellyrix Therapeutics?
The founders of Cellyrix Therapeutics are Eran Kotler, Avishai Gavish, and Mordechai Applebaum.
What is Cellyrix Therapeutics' primary focus?
Cellyrix Therapeutics is focused on introducing a new modality into cancer treatment by harnessing cutting-edge technologies to address tumor heterogeneity, which contributes to therapy resistance, metastasis, and relapse.
What technologies does Cellyrix Therapeutics leverage?
Cellyrix Therapeutics leverages breakthroughs in single-cell sequencing and artificial intelligence to unlock insights into intra-tumor heterogeneity and develop innovative cancer treatments.
Has Cellyrix Therapeutics received any funding?
In December 2024, Cellyrix Therapeutics secured pre-seed funding from AION Labs.
Log in to access full profile